FLASCO
- FLASCO OncoFeature – Nuturing the Next Generation of Oncologists February 21, 2025Press Release by Kellie Jordan RIVERVIEW, FL – February 21, 2025 – Next month, the Florida Society of Clinical Oncology (FLASCO) is holding the annual 2025 FLASCO Fellows & Residents Training Program, a one-day educational event designed to empower and support the next generation of oncology professionals. The program will take place on March 22,...
- FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor February 15, 2025On February 14, 2025, the Food and Drug Administration approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
- FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma February 12, 2025On February 11, 2025, the Food and Drug Administration approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade...
- FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection February 11, 2025On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
- Yttrium-90 Radioembolization in Combination with Tremelimumab and Durvalumab for Treating Patients with Locally Advanced, Unresectable or Oligo-metastatic Intrahepatic Cholangiocarcinoma Who are Not Candidates for Curative Therapy, RAIDEN Trial February 11, 2025This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in treating patients with intrahepatic cholangiocarcinoma (cancer of the bile ducts in the liver) that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable) who are...
- FDA approves treosulfan with fludarabine as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS | FDA February 7, 2025On January 21, 2025, the Food and Drug Administration approved treosulfan (Grafapex, medac GmbH), an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- February is Gallbladder Cancer and Bile Duct Cancer Awareness Month & National Cancer Prevention Awareness Month February 3, 2025Gallbladder cancer and bile duct cancer are relatively rare with an estimated 12,350 cases of both types combined diagnosed in 2024, according to the National Cancer Institute (NCI). The NCI estimated about 4,530 deaths from these cancers in 2024. Cancer of the gallbladder is one of the 15 forms of cancer that have been linked to being overweight...
- Cervical Cancer Awareness Month January 27, 2025Cervical Cancer Awareness Month, also known as Cervical Health Awareness Month, is celebrated in January to raise awareness of cervical cancer and promote prevention, diagnosis, and treatment. Cervical cancer is preventable and curable when it’s detected early and managed effectively. Certain types of human papillomavirus (HPV) are the main cause of cervical cancer.
- January is Cervical Cancer Awareness Month January 27, 2025JOIN WITH THE AACR TO FIND BETTER WAYS TO prevent and TREAT CERVICAL CANCER. While cervical cancer rates in the United States have dropped over the past few decades, the National Cancer Institute projects that approximately 13,820 individuals will be diagnosed with cervical cancer in 2024, and over 4,360 will die from the disease.
- Cervical Cancer Awareness: Empowering Prevention Through the HPV Vaccine January 27, 2025January is Cervical Cancer Awareness Month, dedicated to educating the public about cervical cancer and emphasizing the importance of early detection and prevention. Cervical cancer begins in the cells of the cervix, the lower part of the uterus that connects to the vagina. It usually develops gradually, starting with precancerous changes in cervical cells. The...